|
Match
|
Document |
Document Title |
|
|
7390883 |
PRO4428 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7390635 |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
The present invention provides recombinant peptides that specifically and selectively bind to the human milk fat globule (HMFG) antigen, BA46. In particular, the present invention provides...
|
|
|
7390491 |
Agents comprising midkine or an inhibitor thereof as active ingredient
Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its...
|
|
|
7390488 |
Compositions and methods for producing vascular occlusion
The present invention relates generally to methods and compositions for targeting, delivering, and activating platelet-dependent vascular occlusion agents. In particular, antibodies carrying...
|
|
|
7390486 |
PRO4381 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7388079 |
Delivery of pharmaceutical agents via the human insulin receptor
A humanized murine antibody is provided that binds to the human insulin receptor (HIR). The humanized murine antibody is suitable for use as a Trojan horse to deliver pharmaceutical agents to human...
|
|
|
7387777 |
Methods of treating hemophilia or von willebrand disease with p-selectin
The present invention identifies P-selectin as a modulator of hemostasis. Accordingly, the present invention relates to methods for the identification and use of modulators of P-selectin activity...
|
|
|
7387776 |
Human monoclonal antibodies against CD30
Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of...
|
|
|
7381803 |
Humanized antibodies against CD3
The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric...
|
|
|
7381801 |
Chimerized GM-CSF antibodies
Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically...
|
|
|
7381800 |
Antibodies to HBIMF63 polypeptide
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells,...
|
|
|
7381798 |
Recombinant antibody recognizing dioxin and gene encoding the antibody
The present invention relates to a novel recombinant antibody having a binding activity to 2,3,4,7,8-pentachlorodibenzofuran (2,3,4,7,8-PeCDF), a gene encoding its amino acid sequence, a vector...
|
|
|
7378504 |
Human monoclonal antibodies to Fc gamma receptor I (CD64)
The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to CD64 with high affinity. Nucleic acid molecules encoding the antibodies of the invention,...
|
|
|
7378503 |
Antibodies against insulin-like growth factor 1 receptor and uses thereof
Antibodies which bind to IGF-IR and inhibit the binding of IGF-I and IGF-II to IGF-IR are characterized. These antibodies are implicated in anti-tumor therapy.
|
|
|
7378502 |
PRO4389 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7378501 |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7378275 |
Canine IL-13 receptor alpha-1 subunit nucleic acid molecules
The invention relates to canine immunoglobulin G (IgG) and canine interleukin-13 receptors (IL-13R) as well as fusion proteins containing canine IgG and/or canine IL-13R. In particular, the present...
|
|
|
7378094 |
Therapeutic uses of complement receptor 2
The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune...
|
|
|
7375194 |
Antibodies that bind to an epitope on the Huntington's disease protein
The present invention relates generally to the generation and characterization of anti-huntingtin antibodies binding an epitope on the Huntington's disease protein. The invention further relates to...
|
|
|
7371825 |
Anti-MCP-1 antibodies, compositions, methods and uses
The present invention relates to at least one novel anti-MCP-1 antibodies, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic...
|
|
|
7371817 |
PRO9783 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7371816 |
PRO10284 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7371382 |
Methods of inhibiting αvβ3-mediated binding with αvβ3-specific antibodies
The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to α V β 3 , or a functional fragment thereof. The invention also provides nucleic acid molecules...
|
|
|
7371377 |
Antibodies to polypeptides homologous to VEGF and BMP1
The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor...
|
|
|
7368543 |
Diagnosis and treatment of hepatic disorders
The present invention encompasses methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation. The method comprises administration...
|
|
|
7368535 |
CD200 receptors
The present invention relates to CD200 receptor isoforms and modulators thereof and their use in methods of immune modulation and pharmaceutical compositions.
|
|
|
7368114 |
Fusion protein including of CD4
Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a...
|
|
|
7368111 |
Human antibodies specific for TGFβ2
Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both,...
|
|
|
7365168 |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues...
|
|
|
7365166 |
Anti-VEGF antibodies
Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of...
|
|
|
7365156 |
PRO1316 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7364865 |
Antibodies to myeloid progenitor inhibitory factor-1 (MPIF-1)
There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3...
|
|
|
7364738 |
Monoclonal antibodies to the CLFA protein and method of use in treating infections
Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus , including the active...
|
|
|
7364737 |
Human neutralizing monoclonal antibodies to respiratory syncytial virus
Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also...
|
|
|
7364736 |
Antibodies to OPGL
Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are...
|
|
|
7364735 |
Method for diagnosis and treatment of haemophilia A patients with an inhibitor
A polynucleotide, comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity, or complementary to a nucleotide sequence coding for a human antibody for...
|
|
|
7364731 |
Polypeptide variants
A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326,327, 329, 331, 333...
|
|
|
7361732 |
PRO4400 polypeptides
The present invention is directed to novel polypeptide and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7361344 |
Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke
A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective...
|
|
|
7361341 |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other...
|
|
|
7361338 |
Methods to inhibit growth of prostate cancer cells
A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is...
|
|
|
7358339 |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7358054 |
Antibodies to VLA-1
Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by...
|
|
|
7357927 |
Death domain containing receptors
The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated...
|
|
|
7355018 |
Modified IGF1 polypeptides with increased stability and potency
A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an...
|
|
|
7355013 |
PRO6017 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7355012 |
Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and...
|
|
|
7355011 |
Biological products
There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein...
|
|
|
7355008 |
Identification and engineering of antibodies with variant Fc regions and methods of using same
The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises...
|
|
|
7355007 |
Antibodies that bind PRO5005 Polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|